Extracorporeal life support for adult cardiopulmonary failure

Schaheen, Basil; Thiele, Robert H.; Isbell, James M.

doi:10.1016/j.bpa.2015.04.004

Cited by 14 publications

(5 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the time span of this research, there have been technical advances during the study period, for example, a change from roller pumps to centrifugal pumps, and introduction of wire‐reinforced cannulas with newer non‐thrombogenic coating of the devices, reducing resistance to blood flow with less need for anticoagulation …”

Section: Methodscontrasting

confidence: 68%

Venovenous extracorporeal membrane oxygenation treatment in a low‐volume and geographically isolated cardiothoracic centre

Ingvarsdóttir

Viðarsdóttir

Valsson

et al. 2019

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

Background: Extracorporeal membrane oxygenation (ECMO) treatment is generally offered in large tertiary cardiothoracic referral centres. Here we present the indications and outcome of venovenous-ECMO (VV-ECMO) treatment in a low-volume, geographically isolated single-centre in Iceland, a country of 350 000 inhabitants.Our hypothesis was that patient survival in such a centre can be similar to that at high-volume centres. Methods: A retrospective study that included all patients treated with VV-ECMO inIceland from 1991-2016 (n = 17). Information on demographics, indications and inhospital survival was collected from patient charts and APACHE II and Murray scores were calculated. Information on long-term survival was collected from a centralized registry.Results: Seventeen patients were treated with VV-ECMO (nine males, median age 33 years, range 14-74), the indication for 16 patients was severe acute respiratory distress syndrome, most often following pneumonia (n = 6), H1N1-infection (n = 3) or drowning (n = 2). Median APACHE-II and Murray-scores were 20 and 3.5, respectively, and median duration of VV-ECMO treatment was 9 days (range 2-40 days). In total 11 patients (64,7%) survived the treatment, with 10 patients (58,8%) surviving hospital discharge, all of who were still alive at long-term follow-up, with a median follow-up time of 9 years (August 15th, 2017). Conclusion:Venovenous-ECMO service can be provided in a low-volume and geographically isolated centre, like Iceland, with short-and long-term outcomes comparable to larger centres.

show abstract

Section: Methodscontrasting

confidence: 68%

Venovenous extracorporeal membrane oxygenation treatment in a low‐volume and geographically isolated cardiothoracic centre

Ingvarsdóttir

Viðarsdóttir

Valsson

et al. 2019

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

“…Several techniques have been described in order to decompress the left heart, including intra-aortic balloon pumps (IABPs), axial flow catheters (Impella ® ; Abiomed, Inc., Danvers, MA, USA) and left atrial (LA)-to-femoral artery bypass (TandemHeart ® ; Cardiac Assist, Inc., Pittsburgh, PA, USA). [9][10][11][12] LA decompression has also been achieved by the transcatheter creation of an atrial septal defect (ASD) using different approaches, including vent placement, static balloon dilation and stent implantation. [13][14][15][16][17][18] In this retrospective multicentre study, we aimed to assess the safety and efficiency of percutaneous balloon atrial septostomy (BAS) for left heart decompression in patients on VA-ECMO support.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous balloon atrial septostomy on top of venoarterial extracorporeal membrane oxygenation results in safe and effective left heart decompression

Baruteau

Barnetche

Morin

et al. 2016

European Heart Journal: Acute Cardiovascular Care

View full text Add to dashboard Cite

show abstract

“…This corresponds with improvements in both ECMO console technology (hardware) and associated disposable components (oxygenator, centrifugal pump, and cannulae) that have simplified the technology (2). This new era has seen the role of ECMO amplified to a variety of clinical applications and novel hybrid cannulation configurations (3,4).…”

Section: Overviewmentioning

confidence: 99%

Preserving ECMO Cannulae Patency

McNinch

Searles

Darling

2018

J Extra Corpor Technol

View full text Add to dashboard Cite

Extracorporeal membrane oxygenation (ECMO) is often managed using minimal anticoagulation. This can make the circuitry susceptible to thrombosis. The ECMO cannula may be particularly vulnerable to thrombosis if flow is interrupted for an undetermined but prolonged period of time. Therefore, under conditions where cannula blood flow stasis may be prolonged and flashing, the cannulae is not an option (e.g., air in circuit) it is imperative to have an emergency plan available, which can be rapidly implemented that will provide a means of cannula patency preservation. The following outlines a system to preserve cannula patency in these instances.

show abstract

Extracorporeal life support for adult cardiopulmonary failure

Cited by 14 publications

References 79 publications

Venovenous extracorporeal membrane oxygenation treatment in a low‐volume and geographically isolated cardiothoracic centre

Venovenous extracorporeal membrane oxygenation treatment in a low‐volume and geographically isolated cardiothoracic centre

Percutaneous balloon atrial septostomy on top of venoarterial extracorporeal membrane oxygenation results in safe and effective left heart decompression

Preserving ECMO Cannulae Patency

Contact Info

Product

Resources

About